L04AC16 • guselkumab • Antineoplastic and immunomodulating agents | Immunosuppressants | Interleukin inhibitors
Guselkumabum is a monoclonal antibody used for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. It works by blocking interleukin-23 (IL-23), a protein involved in the chronic inflammation associated with these conditions.
The medication is administered via subcutaneous injection, usually once every few weeks, as directed by a physician. Guselkumabum has shown high efficacy in reducing skin lesions and joint symptoms.
Common side effects include upper respiratory tract infections, headaches, and injection site reactions. It is important for patients to be monitored for signs of infections or other complications.
Guselkumabum provides a modern and effective option for patients with psoriasis and psoriatic arthritis, helping to improve their quality of life.
Substance: guselkumab
Date of last drug list: 01-11-2025
Commercial code: W71369001
Concentration: 200mg
Pharmaceutical form: concentrate for solution for infusion
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: JANSSEN BIOLOGICS B.V. - OLANDA
Holder: JANSSEN-CILAG INTERNATIONAL NV - BELGIA
Number: 1234/2017/05
Shelf life: 2 years